Contineum Therapeutics Class Net Income
| CTNM Stock | 14.30 0.14 0.97% |
As of the 16th of February 2026, Contineum Therapeutics shows the Downside Deviation of 4.61, mean deviation of 3.4, and Risk Adjusted Performance of 0.0996. Contineum Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Contineum Therapeutics coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Contineum Therapeutics is priced correctly, providing market reflects its regular price of 14.3 per share. Given that Contineum Therapeutics has jensen alpha of 0.5567, we suggest you to validate Contineum Therapeutics Class's prevailing market performance to make sure the company can sustain itself at a future point.
Contineum Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Contineum Therapeutics' valuation are provided below:There are over one hundred seventeen available fundamental signals for Contineum Therapeutics Class, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to validate Contineum Therapeutics' prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -48.6 M | -46.2 M | |
| Net Loss | -48.6 M | -46.2 M | |
| Net Loss | (2.51) | (2.39) | |
| Net Income Per E B T | 0.88 | 0.78 |
Contineum | Net Income | Build AI portfolio with Contineum Stock |
Evaluating Contineum Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Contineum Therapeutics Class's fundamental strength.
Latest Contineum Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Contineum Therapeutics Class over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Contineum Therapeutics financial statement analysis. It represents the amount of money remaining after all of Contineum Therapeutics Class operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Contineum Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Contineum Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (42.26 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Contineum Net Income Regression Statistics
| Arithmetic Mean | (28,621,563) | |
| Geometric Mean | 30,640,277 | |
| Coefficient Of Variation | (52.04) | |
| Mean Deviation | 6,554,132 | |
| Median | (29,001,000) | |
| Standard Deviation | 14,894,555 | |
| Sample Variance | 221.8T | |
| Range | 71.3M | |
| R-Value | (0.06) | |
| Mean Square Error | 235.7T | |
| R-Squared | 0 | |
| Significance | 0.81 | |
| Slope | (187,357) | |
| Total Sum of Squares | 3549.6T |
Contineum Net Income History
Other Fundumenentals of Contineum Therapeutics
Contineum Therapeutics Net Income component correlations
Contineum Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Contineum Therapeutics is extremely important. It helps to project a fair market value of Contineum Stock properly, considering its historical fundamentals such as Net Income. Since Contineum Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Contineum Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Contineum Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Pharmaceuticals sector continue expanding? Could Contineum diversify its offerings? Factors like these will boost the valuation of Contineum Therapeutics. Projected growth potential of Contineum fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Contineum Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Contineum Therapeutics requires distinguishing between market price and book value, where the latter reflects Contineum's accounting equity. The concept of intrinsic value - what Contineum Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Contineum Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Contineum Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Contineum Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Contineum Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Contineum Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Contineum Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Contineum Therapeutics.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Contineum Therapeutics on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Contineum Therapeutics Class or generate 0.0% return on investment in Contineum Therapeutics over 90 days. Contineum Therapeutics is related to or competes with Mereo BioPharma, Kyverna Therapeutics, Lexeo Therapeutics, Silence Therapeutics, AC Immune, Alto Neuroscience, and Aldeyra. Contineum Therapeutics is entity of United States More
Contineum Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Contineum Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Contineum Therapeutics Class upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.61 | |||
| Information Ratio | 0.0986 | |||
| Maximum Drawdown | 23.16 | |||
| Value At Risk | (5.55) | |||
| Potential Upside | 7.99 |
Contineum Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Contineum Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Contineum Therapeutics' standard deviation. In reality, there are many statistical measures that can use Contineum Therapeutics historical prices to predict the future Contineum Therapeutics' volatility.| Risk Adjusted Performance | 0.0996 | |||
| Jensen Alpha | 0.5567 | |||
| Total Risk Alpha | 0.178 | |||
| Sortino Ratio | 0.1038 | |||
| Treynor Ratio | (1.75) |
Contineum Therapeutics February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0996 | |||
| Market Risk Adjusted Performance | (1.74) | |||
| Mean Deviation | 3.4 | |||
| Semi Deviation | 4.12 | |||
| Downside Deviation | 4.61 | |||
| Coefficient Of Variation | 884.54 | |||
| Standard Deviation | 4.85 | |||
| Variance | 23.52 | |||
| Information Ratio | 0.0986 | |||
| Jensen Alpha | 0.5567 | |||
| Total Risk Alpha | 0.178 | |||
| Sortino Ratio | 0.1038 | |||
| Treynor Ratio | (1.75) | |||
| Maximum Drawdown | 23.16 | |||
| Value At Risk | (5.55) | |||
| Potential Upside | 7.99 | |||
| Downside Variance | 21.23 | |||
| Semi Variance | 16.94 | |||
| Expected Short fall | (3.64) | |||
| Skewness | 0.4392 | |||
| Kurtosis | 3.07 |
Contineum Therapeutics Backtested Returns
Contineum Therapeutics appears to be somewhat reliable, given 3 months investment horizon. Contineum Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0955, which signifies that the company had a 0.0955 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Contineum Therapeutics Class, which you can use to evaluate the volatility of the firm. Please makes use of Contineum Therapeutics' Downside Deviation of 4.61, mean deviation of 3.4, and Risk Adjusted Performance of 0.0996 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Contineum Therapeutics holds a performance score of 7. The firm shows a Beta (market volatility) of -0.31, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Contineum Therapeutics are expected to decrease at a much lower rate. During the bear market, Contineum Therapeutics is likely to outperform the market. Please check Contineum Therapeutics' semi variance, and the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Contineum Therapeutics' price patterns will revert.
Auto-correlation | 0.49 |
Average predictability
Contineum Therapeutics Class has average predictability. Overlapping area represents the amount of predictability between Contineum Therapeutics time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Contineum Therapeutics price movement. The serial correlation of 0.49 indicates that about 49.0% of current Contineum Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.49 | |
| Spearman Rank Test | 0.3 | |
| Residual Average | 0.0 | |
| Price Variance | 4.44 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Contineum Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Contineum Therapeutics Class reported net income of (42.26 Million). This is 112.38% lower than that of the Pharmaceuticals sector and 160.33% lower than that of the Health Care industry. The net income for all United States stocks is 107.4% higher than that of the company.
Contineum Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Contineum Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Contineum Therapeutics could also be used in its relative valuation, which is a method of valuing Contineum Therapeutics by comparing valuation metrics of similar companies.Contineum Therapeutics is currently under evaluation in net income category among its peers.
Contineum Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Contineum Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Contineum Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Contineum Fundamentals
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.21 | ||||
| Current Valuation | 350.57 M | ||||
| Shares Outstanding | 30.45 M | ||||
| Shares Owned By Insiders | 1.14 % | ||||
| Shares Owned By Institutions | 62.00 % | ||||
| Number Of Shares Shorted | 2.6 M | ||||
| Price To Book | 2.92 X | ||||
| Price To Sales | 11.15 X | ||||
| EBITDA | (42 M) | ||||
| Net Income | (42.26 M) | ||||
| Total Debt | 6.26 M | ||||
| Book Value Per Share | 6.18 X | ||||
| Cash Flow From Operations | (32.84 M) | ||||
| Short Ratio | 9.87 X | ||||
| Earnings Per Share | (2.25) X | ||||
| Target Price | 20.33 | ||||
| Number Of Employees | 41 | ||||
| Market Capitalization | 527.49 M | ||||
| Total Asset | 212.85 M | ||||
| Retained Earnings | (117.4 M) | ||||
| Working Capital | 196.41 M | ||||
| Net Asset | 212.85 M |
About Contineum Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Contineum Therapeutics Class's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Contineum Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Contineum Therapeutics Class based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Will Pharmaceuticals sector continue expanding? Could Contineum diversify its offerings? Factors like these will boost the valuation of Contineum Therapeutics. Projected growth potential of Contineum fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Contineum Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Contineum Therapeutics requires distinguishing between market price and book value, where the latter reflects Contineum's accounting equity. The concept of intrinsic value - what Contineum Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Contineum Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Contineum Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Contineum Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Contineum Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.